References
- Schifferdecker E, Kuhnl P, Schoffling K, et al. Immunogenetic markers in patients with Graves' disease. Klin Wochenschr 1991: 69(6): 256–60
- Alvarado A, Ribeiro JP, Freitas FM, et al. Lack of association between thyroid function and mitral valve prolapse in Graves' disease. Braz J Med Biol Res 1990: 23(2): 133–9
- Solomon B, Glinoer D, Lagasse R, et al. Current trends in the management of Graves' disease. J Clin Endocrinol Metab 1990: 70(6): 1518–24
- Nordyke RA, Gilbert FI Jr. Optimal iodine-131 dose for eliminating hyperthyroidism in Graves' disease. J Nucl Med 1991: 32(3): 411–6
- Marcocci C, Gianchecchi D, Masini I, et al. A reappraisal of the role of methimazole and other factors on the efficacy and outcome of radioiodine therapy of Graves' hyperthyroidism. J Endocrinol Invest 1990: 13(6): 513–20
- Gamstedt A, Karlsson A. Pretreatment with betamethasone of patients with Graves' disease given radioiodine therapy: thyroid autoantibody responses and outcome of therapy. J Clin Endocrinol Metab 1991: 73(1): 125–31
- Gomez JM, Virgili N, Soler J, et al. Transient hypothyroidism after iodine-131 treatment of Graves' disease. Thyroidol Clin Exp 1989: 1(3): 149–52
- Bearcroft CP, Toms GC, Williams SJ, et al. Thyroxine replacement in post-radioiodine hypothyroidism. Clin Endocrinol (Oxf) 1991: 34(2): 115–8 [comment, Clin Endocrinol (Oxf) 1991,34(2): 103–5]
- Banovac K, Carrington SA, Levis S, et al. Determination of replacement and suppressive doses of thyroxine. J Int Med Res 1990: 18(3): 210–8
- Barth A, Probst P, Burgi H. Identification of a subgroup of Graves' disease patients at higher risk for severe ophthalmopathy after radioiodine. J Endocrinol Invest 1991: 14(3): 209–12
- Bartalena L, Marcocci C, Bogazzi F, et al. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 1989: 321(20): 1349–52
- Graham GD, Burman KD. Radioiodine treatment of Graves' disease: an assessment of its potential risks. Ann Intern Med 1986: 105(6): 900–5
- Fold HC, Feek CM, Delahunt JW. Once daily, low dose, short term antithyroid drug treatment of Graves' disease is followed by an unacceptably high relapse rate. NZ Med J 1991: 104(9): 97–8
- Allannic H, Fauchet R, Orgiazzi J, et al. Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab 1990: 70(3): 675–9
- Winsa B, Dahlberg A, Jansson R, et al. Factors influencing the outcome of thyrostatic drug therapy in Graves' disease. Acta Endocrinol (Copenh) 1990: 122(6): 722–8
- Hashizume K, Ichikawa K, Sakurai A, et al. Administration of thyroxine in treated Graves' disease: effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med 1991;324(14): 947–53 [comment, N Engl J Med 1991;324(14): 989–90; N Engl J Med 1991: 325(9): 660–1]
- Tajiri J, Noguchi S, Murakami T, et al. Antithyroid drug—induced agranulocytosis: the usefulness of routine white blood cell count monitoring. Arch Intern Med 1990: 150(3): 621–4
- Kuma K, Matsuzuka F, Kobayashi A, et al. Natural course of Graves' disease after subtotal thyroidectomy and management of patients with postoperative thyroid dysfunction. Am J Med Sci 1991: 302(1): 8–12
- Messer PM, Hauffa BP, Olbricht T, et al. Antithyroid drug treatment of Graves' disease in pregnancy: long-term effects on somatic growth, intellectual development and thyroid function of the offspring. Acta Endocrinol (Copenh) 1990: 123(3): 311–6
- Prummel MF, Mourits MP, Berghout A, et al. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. N Engl J Med 1989: 321(20): 1353–9
- van der Gaag R, Wiersinga WM, Koornneef L, et al. HLA-DR4 associated response to corticosteroids in Graves' ophthalmopathy patients. J Endocrinol Invest 1990: 13(6): 489–92
- Petersen IA, Kriss JP, McDougall IR, et al. Prognostic factors in the radiotherapy of Graves' ophthalmopathy. Int J Radiat Oncol Biol Phys 1990: 19(2): 259–64
- Saras HP, Notz RG, Saul RF, et al. Severe dysthyroid orbitopathy. Trans Pa Acad Ophthalmol Otolaryngol 1990: 42: 981–4
- Wilson WB, Manke WF. Orbital decompression in Graves' disease: the predictability of reduction of proptosis. Arch Ophthalmol 1991: 109(3): 343–5
- Olivari N. Transpalpebral decompression of endocrine ophthalmopathy (Graves' disease) by removal of intraorbital fat: experience with 147 operations over 5 years. Plast Reconstr Surg 1991;87(4): 627–41 [discussion, Plast Reconstr Surg 1991: 87(4): 642–3]